Welcome to our dedicated page for Dupont De Nemours SEC filings (Ticker: DD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DuPont de Nemours, Inc. filings document the regulatory disclosures of a Delaware specialty materials company with common stock listed on the New York Stock Exchange under DD. Its 8-K reports cover operating and financial results, Regulation FD disclosures, material events, board composition changes, corporate-governance matters and capital-structure disclosures.
DuPont proxy materials describe annual stockholder voting matters, director elections, governance practices, executive compensation and proposals affecting the company’s certificate of incorporation and common stock. Recent filings also document separation-related matters, including disclosures connected with the completed Qnity Electronics spin-off, as well as agreements and percentage calculations tied to the post-separation corporate structure.
DuPont de Nemours, Inc. reported that it has amended its previously announced exchange offers for its outstanding 4.725% Notes due 2028 in the principal amount of $2,250,000,000, 5.319% Notes due 2038 in the amount of $1,000,000,000 and 5.419% Notes due 2048 in the amount of $2,150,000,000.
The company is offering to exchange these existing notes for new notes issued by DuPont and is concurrently conducting consent solicitations from eligible holders of each series to adopt amendments to the relevant indentures. The amended terms are described in a confidential offering memorandum and a related supplement, with additional details contained in a press release attached as an exhibit.
DuPont de Nemours, Inc. reported that it has amended its previously announced exchange offers for its outstanding 4.725% Notes due 2028 in the principal amount of $2,250,000,000, 5.319% Notes due 2038 in the amount of $1,000,000,000 and 5.419% Notes due 2048 in the amount of $2,150,000,000.
The company is offering to exchange these existing notes for new notes issued by DuPont and is concurrently conducting consent solicitations from eligible holders of each series to adopt amendments to the relevant indentures. The amended terms are described in a confidential offering memorandum and a related supplement, with additional details contained in a press release attached as an exhibit.
DuPont de Nemours insider activity: Steven P. Larrabee, Senior Vice President & Chief Information Officer, reported option exercise and sales in early September 2025. On 09/04/2025 he exercised 25,000 stock options with an exercise price of $66.06 (code M), resulting in acquisition of 25,000 shares. He sold 25,000 shares on 09/04/2025 at $76.50 and sold an additional 6,000 shares on 09/05/2025 at $78.00. After these transactions he beneficially owned 42,585.1905 shares directly and 147.2117 shares indirectly through the Retirement Savings Plan. The filing notes dividend reinvestment contributed to the reported holdings and that the exercised options were fully exercisable as of 12/31/2021.
Form 144 notice for DuPont de Nemours, Inc. (DD) reports a proposed sale of 92,248 shares of Common stock through Merrill Lynch at 3455 Peachtree Road NE, Atlanta, GA, with an aggregate market value of $7,525,332.00. The filing lists the approximate date of sale as 09/04/2025 and the securities exchange as the NYSE.
The table of acquisition history shows most shares were received as compensatory stock awards from DuPont de Nemours, Inc., including an exercise of stock awards on 09/04/2025 (recorded as 82,248 shares) and multiple vesting events in 2022–2023 (1,865; 5,726; 420; 1,989). The filer certifies they are unaware of undisclosed material adverse information in the issuer.
Insider purchase via dividend reinvestment: Director Frederick M. Lowery acquired 503.7702 shares of DuPont de Nemours, Inc. (DD) on 08/29/2025 at a reported price of $76.92 per share, increasing his direct beneficial ownership to 33,270.0198 shares. The filing notes the acquisition includes shares purchased through a dividend reinvestment program. The Form 4 was signed by Peter W. Hennessey by power of attorney on 09/03/2025.
Cutler Alexander M, identified as a Director of DuPont de Nemours, Inc. (Ticker: DD), reported a purchase of 650.026 shares of DuPont common stock on 08/29/2025 at a price of $76.92 per share. The filing states the acquisition includes shares received through dividend reinvestment.
After this transaction, Mr. Cutler is reported to beneficially own 73,879.0062 shares in a direct ownership form. The Form 4 was signed by power of attorney on 09/03/2025 by Peter W. Hennessey.
Terrence R. Curtin, a director of DuPont de Nemours, Inc. (DD), reported an open-market acquisition on 08/29/2025. The Form 4 shows he acquired 422.5169 shares of DuPont common stock at a price of $76.92 per share, with the filing noting the acquisition includes shares received through dividend reinvestment. After the transaction, Mr. Curtin beneficially owned 30,966.5213 shares in total, including 7,500 shares held indirectly through family trusts.
The Form 4 was signed by Peter W. Hennessey by power of attorney on 09/03/2025. The filing lists Mr. Curtin's address in Wilmington, DE, and identifies his relationship to the issuer as a director.
Amy G. Brady, a director of DuPont de Nemours, Inc. (DD), reported a non-derivative purchase of common stock on 08/29/2025. The Form 4 shows an acquisition of 105.6292 shares at a price of $76.92 per share, bringing her total reported beneficial ownership to 19,274.5372 shares, held directly. The filing includes a disclosure that the total includes shares acquired through dividend reinvestment. The filing was submitted with a signature dated 09/03/2025 by Peter W. Hennessey by power of attorney.
DuPont announced a definitive agreement to sell its Aramids business (Kevlar4 and Nomex4) to Arclin for an enterprise value of approximately $1.8 billion. Under the Transaction Agreement, DuPont will receive roughly $1.2 billion in pre-tax cash at closing (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at $325 million, expected to represent about a 17.5% ownership at closing. The agreement is conditioned on customary closing requirements, including regulatory approvals in multiple non-U.S. jurisdictions and satisfactory representations, warranties and performance by the parties.
DuPont agreed to sell its Aramids business (Kevlar® and Nomex®) to Arclin, a portfolio company of an affiliate of TJC, L.P., in a transaction valuing the business at approximately $1.8 billion. At closing DuPont is expected to receive approximately $1.2 billion in pre-tax cash proceeds (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at about $325 million (approximately 17.5% at closing). The sale is conditioned on customary closing conditions, including regulatory approvals. The information is disclosed in a press release embedded in the company’s 8-K filing.
DuPont agreed to sell its Aramids business (Kevlar® and Nomex®) to Arclin, a portfolio company of an affiliate of TJC, L.P., in a transaction valuing the business at approximately $1.8 billion. At closing DuPont is expected to receive approximately $1.2 billion in pre-tax cash proceeds (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at about $325 million (approximately 17.5% at closing). The sale is conditioned on customary closing conditions, including regulatory approvals. The information is disclosed in a press release embedded in the company’s 8-K filing.
DuPont agreed to sell its Aramids business (Kevlar® and Nomex®) to Arclin, a portfolio company of an affiliate of TJC, L.P., in a transaction valuing the business at approximately $1.8 billion. At closing DuPont is expected to receive approximately $1.2 billion in pre-tax cash proceeds (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at about $325 million (approximately 17.5% at closing). The sale is conditioned on customary closing conditions, including regulatory approvals. The information is disclosed in a press release embedded in the company’s 8-K filing.
Edward D. Breen, Executive Chair and director of DuPont de Nemours (DD), reported changes in his beneficial ownership of common stock. On 08/12/2025 he received 13,754 shares as annuity payments from prior 2021 GRATs and through dividend reinvestment, bringing his post-transaction holdings to 165,405.7751 shares. On 08/20/2025 he recorded a disposition of 28,111 shares related to funding a new GRAT (2025-7), leaving 137,294.7511 shares beneficially owned. The filing notes the 13,754 shares were received at no cash price and the 28,111 shares were disposed of at no cash price. The report was submitted by power of attorney.